Back to Search
Start Over
Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors
- Source :
- Medicine
- Publication Year :
- 2018
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2018.
-
Abstract
- To compare long-term overall survival (OS) in patients with G1 and G2 grade Ta bladder cancer after transurethral resection of bladder tumors (TURBTs). Secondary aim was to investigate clinical and pathologic prognostic factors for OS of Ta patients, except G3/high grade (HG). A total of 243 patients, retrospectively selected, with Ta nonmuscle invasive bladder cancer (NMIBC) underwent TURBT between January 2006 and December 2008 (median follow-up 109 months). Inclusion criteria were: Ta at first manifestation, G1 or G2 grade with no associated carcinoma in situ (CIS). Seventy-nine patients were excluded due to concomitant CIS (1), G3/HG tumors (47), and lost to follow-up (31). Ethical approval was obtained from the Ethical Committee of the Mures County Hospital. Statistical analysis was performed using STATA 11.0. Following inclusion criteria, 164 patients with primary G1 or G2 Ta tumors, were enrolled. Recurrence was observed in 26 (15.8%) and progression in 5 (3%) patients. Ten-year survival in G1 patients was 67.8% (CI 54.3–78.1) and in G2 patients 59% (CI 49–67.3) (P = .31). Univariable and multivariable logistic regression analysis underlined that advanced age at diagnosis (hazard ratio [HR] 1.10) and no Bacillus Calmette–Guerin (BCG) treatment (HR 0.24 and 0.29) were independent predictors for death at 10 years after diagnosis. Long-term analysis confirms that patients with well differentiated (G1) and moderately well differentiated (G2) Ta tumors have similar OS. A longer OS was even reported in those who underwent BCG adjuvant therapy.
- Subjects :
- Male
G1 and G2 grade nonmuscle invasive bladder cancer
medicine.medical_treatment
030232 urology & nephrology
Long-term
Overall survival
Progression
Recurrence
Adjuvants, Immunologic
BCG Vaccine
Combined Modality Therapy
Female
Humans
Middle Aged
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Neoplasm Staging
Prognosis
Risk Assessment
Romania
Survival Analysis
Carcinoma, Transitional Cell
Cystectomy
Urinary Bladder Neoplasms
Medicine (all)
0302 clinical medicine
Immunologic
General Medicine
Local
030220 oncology & carcinogenesis
Research Article
medicine.medical_specialty
recurrence
overall survival
Urology
Observational Study
Resection
03 medical and health sciences
medicine
Carcinoma
In patient
Adjuvants
Survival analysis
long-term
Bladder cancer
business.industry
medicine.disease
Neoplasm Recurrence
progression
Transitional Cell
business
BCG vaccine
Subjects
Details
- ISSN :
- 00257974
- Volume :
- 97
- Database :
- OpenAIRE
- Journal :
- Medicine
- Accession number :
- edsair.doi.dedup.....07072ce09e71a32d5fae1a1278d063bc
- Full Text :
- https://doi.org/10.1097/md.0000000000010522